Market revenue in 2023 | USD 503.7 million |
Market revenue in 2030 | USD 2,314.9 million |
Growth rate | 24.3% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Allogeneic Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allogeneic Therapies, Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Key Regions: U.S. , UK , Japan , Canada , Switzerland
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 99.84% in 2023. Horizon Databook has segmented the Germany cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The Germany cell therapy market is expected to grow significantly over the forecast period. The presence of a substantial number of manufacturers of cell therapies and initiatives undertaken by them to expand their businesses are expected to support the market growth. Numerous companies operating in the country are undertaking strategies like partnerships and acquisitions to remain competitive in the market.
For instance, in July 2020, Boehringer Ingelheim, a company operating in Germany, acquired a Belgian veterinary biotechnology organization, Global Stem Cell Technology (GST), to boost its stem cell therapies abilities. Such acquisitions are expected to boost the market in Germany.
Germany has many institutes and universities engaged in stem cell research, thereby boosting revenue generation in the country. Moreover, conferences and workshops on human stem cell technology held in the region are expected to drive the regional market. Furthermore, advancements in clinical applications of stem cell therapy and the growing approvals for cell therapy are expected to boost the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Germany cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account